Day 4 Program

General Session 3

Day 4: December 11, 2026

9:15 AM–11:45 AM CST

Hall 1

Session Details

Moderator

Sarat Chandarlapaty, Memorial Sloan Kettering Cancer Center, New York, NY

Moderator

Shou-Ching Tang, LSU School of Medicine, New Orleans, New Orleans, LA

GS3-3

Discussant

Aditya Bardia, University of California Los Angeles, Los Angeles, CA

GS3-4

Characterization of clinical outcomes in monarchE by histologic, molecular, and genomic subtypes: Updated baseline tumor analysis from patients with HR+, HER2−, node-positive, high-risk early breast cancer

Nick Turner, Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

GS3-5

Longitudinal analysis of imaging biomarkers and ctDNA to predict neoadjuvant therapy response: a retrospective study from I-SPY 2

Wen Li, University of California, San Francisco, San Francisco, CA

GS3-6

Translational discovery and validation of genomic alterations associated with AKT inhibitor (AKTi) resistance in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- MBC)

Maxwell R Lloyd, Massachusetts General Hospital, Boston, MA

GS3-7

Vaccination to target PARP inhibitor resistance caused by BRCA1/2 reversion mutations

Stephen J. Pettitt, Institute of Cancer Research, London, United Kingdom

GS3-8

Efficacy and safety of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy versus standard of care (SoC) therapy in stage I-II HER2+ early breast cancer (eBC): First results from WSG ADAPT-HER2-IV

Nadia Harbeck, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany

GS3-10

The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab – Outcomes in Patients (pts) with HER2+ Metastatic Breast Cancer (MBC) (TBCRC 062)

Heather A Parsons, Fred Hutchinson Cancer Center, Seattle, WA